Navigation Links
Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
Date:5/23/2013

on to the Increased Offer or any other matters referred to in this announcement.

BofA Merrill Lynch, together with its affiliate Merrill Lynch International (which is authorised and regulated by the Financial Conduct Authority in the United Kingdom), is acting exclusively for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be, responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to clients of BofA Merrill Lynch or its affiliates or for providing advice in relation to the Increased Offer or any other matters referred to in this announcement.

Groton Partners is acting exclusively for Royalty Pharma and RP Management in connection with the matters described in this announcement and for no one else, and is not, and will not be, responsible to anyone other than Royalty Pharma and RP Management for providing the protections afforded to its clients or for providing advice in relation to the Increased Offer or any other matters referred to in this announcement.

Forward-looking Statements

This announcement may include certain "forward looking statements" with respect to the business, strategy and plans of Royalty Pharma and its expectations relating to the Increased Offer and Elan's future financial condition and performance. Statements that are not historical facts, including statements about Elan or Royalty Pharma or Royalty Pharma's belief and expectation, are forward looking statements. Words such as "believes", "anticipates", "estimates", "expects", "intends", "aims", "potential", "will", "would", "could", "considered", "likely", and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements. By their nature, forward looking statements involve risk
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Royalty Rates Take Center Stage in Biopharma Dealmaking
2. Royalty Pharma Announces Proposal To Acquire Elan
3. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
4. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
5. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
6. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
7. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
8. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
9. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
10. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 ... the addition of the "Endoscopy Global Market ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... approximately $43 billion by 2019 growing at around ... drivers for the market growth are aging population, ...
(Date:4/27/2015)... April 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced ... of lonafarnib in patients with chronic hepatitis delta viral ... program, enrolled at Ankara University Medical School, ... endemic. LOWR HDV - 1 (LOnafarnib ... study which randomized subjects to receive different doses of ...
(Date:4/27/2015)... di Reggio Emilia, the Regional Health Service office for ... Zebra Technologies Corporation (NASDAQ: ZBRA ) wireless ... (WNS) provided by Zebra has allowed staff to ... via mobile computers, contributing to improved patient care with ... and guest Wi-Fi access and enables hospital staff to ...
Breaking Medicine Technology:Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... Corporation (NYSE: SGP ) today reported that interim ... (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent ... virus (HCV) genotype 1. In the lead-in arms ... lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) ...
... Sciences, Inc. (Nasdaq: CALP ), a leading provider of ... from the United States Food and Drug Administration (FDA) on ... screening and characterization assays for biological drugs. , "We were ... platform to a large group of reviewers. We believe the ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2
(Date:4/27/2015)... Clyde, NC (PRWEB) April 27, 2015 ... residents will conclude a social media campaign to raise ... and developer, Michael Mamas; and Sri Somesvara Temple. Ironically, ... Ridge Mountains of North Carolina, they thought they were ... commit to at least six months of meditation, service ...
(Date:4/27/2015)... 2015 Telematics Berlin is Europe’s biggest ... associations, CE players and the government to discuss the ... the car. This year’s panel on connected car security ... European Commission, is an opportunity to hear and contribute ... European Automotive Security Standard for years to come. ...
(Date:4/27/2015)... Chicago and its seven surrounding counties ... make area communities healthier, more sustainable and more beautiful. ... every five parkway trees likely to soon be destroyed ... this tree “tipping point,” Chicago-area residents are concerned, as ... Morton Arboretum . The Lisle, Illinois-based tree-focused institution’s Talking ...
(Date:4/27/2015)... The global coagulation analyzers market is estimated to ... however, it is expected to witness high growth ... Brazil in the next five years. Growth in ... such as increasing adoption of automated hemostasis instruments ... developments in high-sensitivity point-of-care coagulation analyzers and introduction ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Mount Soma Monks Do Social Media 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 2Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 4Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... A new study shows obesity may increase the risk ... by researchers at the National Institutes of Health, reveals ... adenocarcinoma than with squamous cell carcinoma. ,The study ... carcinoma, and 307 women without cancer as the control ...
... year, about 12,000 cases of cancer of the larynx are ... will have to have a laryngectomy// - taking away their ... new alternative that's giving patients their voices back. ,For ... no voice. "Some things you do not forget, and that ...
... to prevent bone loss may also help prevent prostate cancer ... United Kingdom indicates oral sodium clodronate may slow the spread ... death. //This is a drug commonly used to prevent bone ... in about 85 percent of men. The researchers recruited 311 ...
... done previously have shown that the hormone could suppress ... would not work in obese people because studies of another ... do a second trial to see if obese people were ... they are. They're just as sensitive as thin people." ...
... to eat healthier. A new study finds whole grains, fruits ... your overall risk of dying. However, the study also reports ... stroke. ,The U.S. Dietary Guidelines for Americans include choosing ... variety of grains daily, especially whole grains. While at least ...
... who suffer from asthma do not meet the right ... activity// of adults with asthma. Knowing if asthma patients ... health professionals in designing fitness programs for asthma patients. ... Prevention conducted a study to look at the physical ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Extra hormone found to cut appetite by a third 2
... compact system provides an ideal solution ... the laboratory, satellite lab and the ... staining method with wedge-smear technology, the ... standardization in a safe enclosed environment. ...
It is a cardio-pulmonary exercise testing device....
... Q-Stress Treadmill has digitally-controlled drive ... moving parts that can wear out. ... speed change mechanism, and fewer drive ... level of dependability. It can carry ...
... feature our internationally-acclaimed algorithm that is ... has a proven record for reliability ... and it's just one of several ... market leader in the stress testing ...
Medicine Products: